Teva Pharmaceuticals
TEVA
522 hedge funds and large institutions have $10.5B invested in Teva Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 162 increasing their positions, 183 reducing their positions, and 79 closing their positions.
0% less capital invested
Capital invested by funds: $10.6B → $10.5B (-$21.8M)
1.12% less ownership
Funds ownership: 62% → 60.88% (-1.1%)
5% less funds holding
Funds holding: 552 → 522 (-30)
10% less call options, than puts
Call options by funds: $303M | Put options by funds: $338M
11% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 183
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
33% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$237M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$110M |
| 3 |
O
OrbiMed
New York
|
+$71.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$64.2M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$61.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$321M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$115M |
| 3 |
BC
Brahman Capital
New York
|
-$91.4M |
| 4 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$76.2M |
| 5 |
Renaissance Technologies
New York
|
-$76.1M |
TEVA Hedge Fund Activity: Q1 2019 in Review
522 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2019, worth a combined $10.5B — down 0.21% from $10.6B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of TEVA and 53 opened new positions — a net loss of 26 holders — while 183 trimmed existing stakes and 162 added.
The largest buyer was Wellington Management Group, adding an estimated $237M. The largest seller was Fidelity Investments, cutting an estimated $321M.
- 522 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2019, down from 552 in Q4 2018.
- Funds reported $10.5B of Teva Pharmaceuticals stock for Q1 2019, down 0.21% quarter-over-quarter.
- 53 funds opened new Teva Pharmaceuticals positions in Q1 2019 and 79 closed out, a net change of -26 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2019 was Wellington Management Group, an estimated $237M added.
- The largest Teva Pharmaceuticals seller in Q1 2019 was Fidelity Investments, an estimated $321M sold.
Based on aggregated 13F filings for Q1 2019.